About
Welcome to the inaugural Targeted Radiopharmaceuticals US Summit
The new Targeted Radiopharmaceuticals US Summit will unite a global community of experts as they look to overcome long-standing roadblocks in radiopharmaceutical development at all phases, from bench to bedside. Join them in Boston this July as they uncover the most critical methods to maximize the value of their medicines to make them not only more financially viable but to accelerate the number of patients who will benefit from them.
Join us to:
- Make the most of current enthusiasm and investment in the industry by making sound strategic decisions that will propel your pipeline forward to approval.
- Conduct clinical studies to address the current unmet clinical needs and improve the lives of your patients
- Assist in the development of a strong radiopharmaceutical community that will allow this venerable technology to achieve new heights.
Don’t miss your only annual opportunity to collaborate with pioneers in the space and explore the value of theragnostic radionuclide therapies within advanced oncology portfolios.
Five Key Reasons to Attend
Optimize your clinical trials by ensuring you use strong design methodology, identify clinical sites that will meet your needs sufficiently, and maintain a consistent supply of your compound with Clarity Pharmaceuticals
Identify new therapeutic potential in your products by discussing a broader range of cancers beyond prostate including metastases of neurological cancers and hematological with Boston Children’s Hospital and Cellectar Biosciences
Take an in-depth look at how the recent influx of investment is reshaping the field and also hear from Brookline Capital Markets what they are looking for when a new company comes through the door
Use dosimetry with greater confidence with our dosimetry workshop being led by leading organizations in dosimetry with the Cancer Research Institute of Montpellier
Design rational combinations including theranostic/ diagnostic pairings that elucidate your understanding of drug delivery. As well as the potential of enhancing therapeutic effectiveness through combination with DNA Damage response agents with Bayer and Viewpoint MT
